INT332658

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.01
First Reported 2010
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 1
Disease Relevance 0.48
Pain Relevance 0.25

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Golgi apparatus (Laptm4a)
Laptm4a (Mus musculus)
Pain Link Frequency Relevance Heat
Bioavailability 1 94.52 High High
ischemia 25 81.68 Quite High
headache 3 68.88 Quite High
carbamazepine 1 58.96 Quite High
cva 98 50.00 Quite Low
sodium channel 3 41.08 Quite Low
spinal-cord stimulation 19 5.00 Very Low Very Low Very Low
depression 11 5.00 Very Low Very Low Very Low
Pain 6 5.00 Very Low Very Low Very Low
tolerance 5 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Cv Unclassified Under Development 36 81.68 Quite High
Dizziness 4 69.76 Quite High
Headache 3 68.88 Quite High
Vomiting 1 67.76 Quite High
Coronary Heart Disease 3 67.56 Quite High
Coronary Artery Disease 33 63.80 Quite High
Cv General 3 Under Development 97 50.00 Quite Low
Cv General 2 Under Development 4 37.96 Quite Low
Myocardial Stunning 4 33.60 Quite Low
Injury 1 27.12 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Ranolazine is cleared by the hepatic enzymes CYP3A4 (70%–85%) and CYP2D6 (10%–15%) and is also a substrate of P-glycoprotein, a widely expressed membrane transporter protein.89 P-glycoprotein inhibitors, such as cyclosporine, reduce the dose of ranolazine needed to produce a given response.
Gene_expression (expressed) of transporter protein
1) Confidence 0.01 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2941787 Disease Relevance 0.48 Pain Relevance 0.25

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox